The month ahead: July’s upcoming events
Regeneron is facing two FDA decisions for its T-cell engagers.
Astra looks to confirm Datroway's turnaround
The Avanzar study could read out shortly.
TuHura makes its bid for Merkel accelerated approval
The company reckons its immunotherapy could improve on Keytruda.
A solid tumour Car-T first?
Satri-cel is filed for gastric cancer approval in China.
Deals accompany new phase 1 trial starts
First-in-human studies include a new pan-KRAS inhibitor and CDK2/4 degrader.
Revolution mortgages royalties for more cash
“We need all the capital we can get our hands on," the company states.
Better late than never for Datroway in lung cancer
Astra/Daiichi have trumped Gilead’s Trodelvy with a lung cancer approval.
Nuvalent loses ground in the front line
Zidesamtinib is having a hard time catching up with Ibtrozi's line-agnostic approval.
Lunsumio steps into Columvi territory
Sunmo succeeds in a setting very similar to Starglo's.
ArriVent goes Further into PACC mutations
The group is aiming for accelerated approval with the upcoming Alpacca trial.
